We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Premature Babies Not Aided by NO

By HospiMedica staff writers
Posted on 01 Aug 2005
Inhaled nitric oxide therapy for lung problems in pre-term infants does not reduce the infant's chances for death or further lung problems, according to a study in the July 7, 2005, issue of The New England Journal of Medicine.

Inhaled nitric oxide is effective for treating full-term infants with lung complications. More...
In term infants, whose lungs are fully formed, these complications result from lung infection. For the treatment, nitric oxide gas is mixed with oxygen and given to an infant through a breathing apparatus. The treatment relaxes the blood vessels in the lungs, allowing the lungs to absorb oxygen more easily. Because this treatment helps infants, researchers had been interested in its possible use to treat lung complications in preterm babies.

A team of researchers with the U.S. National Institute of Child Health and Human Development (NICHD, Bethesda, MD, USA; www.nichd.nih.gov) enrolled 420 infants born at less than 34 weeks' gestation, weighing between 14 ounces to three pounds, two ounces. All infants required assisted ventilation and had a diagnosis of respiratory distress syndrome, sepsis or pneumonia, or other breathing problems. The infants were randomly assigned to receive either inhaled nitric oxide or a placebo.

The results showed no difference between the infants who received the inhaled nitric oxide and those who did not: 60% of infants who received it and 68% of those who did not developed bronchopulmonary dysplasia, a serious lung condition involving lung inflammation and scarring. Both groups had high death rates (52% in the inhaled nitric oxide group and 44% in the placebo group.)

"Contrary to our hopes as neonatologists, inhaled nitric oxide treatment did not reduce the incidence of death or further lung problems,” said co-author Dr. Rosemary Higgins, of NICHD's pregnancy and perinatology branch. "The smallest and sickest of infants were not sufficiently developed.”

The researchers found that infant weight affected the outcome among infants receiving inhaled nitric oxide. Infants in this group weighing between 1,000 and 1,500 g had a significantly lower death rate than infants in the placebo group. Infants weighing less than 1,000 grams in this group had a higher death rate than those in the placebo group. In addition, infants receiving inhaled nitric oxide through conventional mechanical ventilation had a higher mortality rate than those receiving the therapy through high-frequency ventilation.

"We have more work to do to better understand how to best help premature infants with severe lung problems,” observed Dr. Higgins.




Related Links:
NICHD

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.